STOCK TITAN

BioXcel Therapeutics Inc - BTAI STOCK NEWS

Welcome to our dedicated news page for BioXcel Therapeutics (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on BioXcel Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioXcel Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioXcel Therapeutics's position in the market.

Rhea-AI Summary
BioXcel Therapeutics, Inc. (BTAI) will release its Q4 and full year 2023 financial results on March 12, 2024. The company uses AI for neuroscience and immuno-oncology drugs. A conference call and webcast will discuss the results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. terminates a $60.0 million public offering due to unfavorable market conditions. The company shifts focus to FDA meeting for Phase 3 trial of BXCL501 in treating agitation associated with dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.15%
Tags
offering
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. receives FDA Fast Track designation for BXCL701 in combination with a checkpoint inhibitor for treating metastatic small cell neuroendocrine prostate cancer. The company plans to discuss the registration path with the FDA, highlighting the potential of BXCL701 in addressing unmet medical needs in SCNC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
clinical trial
Rhea-AI Summary
BioXcel Therapeutics, Inc. has announced an underwritten public offering of $60.0 million of shares of its common stock, with an option to purchase additional shares. The net proceeds will be used to fund ongoing and planned clinical trials, commercialization, and general corporate purposes. The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC. BofA Securities and Truist Securities are acting as joint book-running managers for the proposed public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.73%
Tags
offering
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. announced the completion of patient enrollment in the safety lead-in portion of the Phase 2 trial of BXCL701 in combination with KEYTRUDA in pancreatic cancer. Initial study data is expected in 2024. The trial is evaluating BXCL701, an oral innate immune activator, and is expected to begin the human proof of concept portion in H1 2024. The company aims to address the significant unmet medical need in treating advanced pancreatic cancer, which has a low survival rate. Preclinical studies have shown encouraging results, and the company is optimistic about the potential of BXCL701 in combination with KEYTRUDA for this indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
clinical trial
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. announces the issuance of a new patent for the treatment of agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. This strengthens the company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients. The patent is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment, patent term extension, and terminal disclaimers. Additionally, the company has received an issue notification for another patent related to the treatment of agitation associated with schizophrenia or bipolar disorder through oromucosal administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
none
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to review BXCL502 and other potential emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss BXCL502 as a potential treatment for chronic agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid withdrawal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announces the promotion of Vincent J. O’Neill, M.D., to Executive Vice President, Chief of Product Development and Medical Officer, and the appointment of Rajiv Patni, M.D., as Strategic Clinical Advisor to the CEO and Board of Directors. The company emphasizes a strategic reprioritization focused on advancing late-stage clinical programs and emerging pipeline candidates. O’Neill's promotion and Patni's appointment aim to strengthen clinical leadership in line with the prioritization of late-stage TRANQUILITY and SERENITY III programs for BXCL501’s potential use to treat Alzheimer’s, bipolar disorder, and schizophrenia-related agitation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
clinical trial
-
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid withdrawal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced plans to conduct Phase 3 trials of BXCL501 in the at-home setting for the TRANQUILITY program, targeting the acute treatment of agitation associated with dementia due to probable Alzheimer’s disease. The FDA's recommendation for a Phase 3 trial aligns with the Company's plans. The company also provided an update on strategic financing activities and reported its financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.41%
Tags
earnings clinical trial
BioXcel Therapeutics Inc

Nasdaq:BTAI

BTAI Rankings

BTAI Stock Data

97.53M
20.73M
29.78%
31.42%
24.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Haven

About BTAI

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.